1
|
TAN T, Parikh R, Mahapatra A, Perkins R, Go A. WCN23-0469 IgA NEPHROPATHY AND RISKS OF KIDNEY AND CARDIOVASCULAR EVENTS AND DEATH: THE KNIGHT STUDY. Kidney Int Rep 2023. [DOI: 10.1016/j.ekir.2023.02.614] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/22/2023] Open
|
2
|
Dubrot J, Du PP, Lane-Reticker SK, Kessler EA, Muscato AJ, Mehta A, Freeman SS, Allen PM, Olander KE, Ockerman KM, Wolfe CH, Wiesmann F, Knudsen NH, Tsao HW, Iracheta-Vellve A, Schneider EM, Rivera-Rosario AN, Kohnle IC, Pope HW, Ayer A, Mishra G, Zimmer MD, Kim SY, Mahapatra A, Ebrahimi-Nik H, Frederick DT, Boland GM, Haining WN, Root DE, Doench JG, Hacohen N, Yates KB, Manguso RT. In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer. Nat Immunol 2022; 23:1495-1506. [PMID: 36151395 DOI: 10.1038/s41590-022-01315-x] [Citation(s) in RCA: 46] [Impact Index Per Article: 23.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2022] [Accepted: 08/15/2022] [Indexed: 02/04/2023]
Abstract
The immune system can eliminate tumors, but checkpoints enable immune escape. Here, we identify immune evasion mechanisms using genome-scale in vivo CRISPR screens across cancer models treated with immune checkpoint blockade (ICB). We identify immune evasion genes and important immune inhibitory checkpoints conserved across cancers, including the non-classical major histocompatibility complex class I (MHC class I) molecule Qa-1b/HLA-E. Surprisingly, loss of tumor interferon-γ (IFNγ) signaling sensitizes many models to immunity. The immune inhibitory effects of tumor IFN sensing are mediated through two mechanisms. First, tumor upregulation of classical MHC class I inhibits natural killer cells. Second, IFN-induced expression of Qa-1b inhibits CD8+ T cells via the NKG2A/CD94 receptor, which is induced by ICB. Finally, we show that strong IFN signatures are associated with poor response to ICB in individuals with renal cell carcinoma or melanoma. This study reveals that IFN-mediated upregulation of classical and non-classical MHC class I inhibitory checkpoints can facilitate immune escape.
Collapse
Affiliation(s)
- Juan Dubrot
- Broad Institute of MIT and Harvard, Cambridge, MA, USA
- Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA
- Department of Medicine, Massachusetts General Hospital, Boston, MA, USA
- Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain
| | - Peter P Du
- Broad Institute of MIT and Harvard, Cambridge, MA, USA
- Stanford University School of Medicine, Stanford, CA, USA
| | | | | | | | - Arnav Mehta
- Broad Institute of MIT and Harvard, Cambridge, MA, USA
- Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA
- Department of Medicine, Massachusetts General Hospital, Boston, MA, USA
| | - Samuel S Freeman
- Broad Institute of MIT and Harvard, Cambridge, MA, USA
- Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA
- Department of Medicine, Massachusetts General Hospital, Boston, MA, USA
| | - Peter M Allen
- Broad Institute of MIT and Harvard, Cambridge, MA, USA
| | | | | | - Clara H Wolfe
- Broad Institute of MIT and Harvard, Cambridge, MA, USA
| | | | - Nelson H Knudsen
- Broad Institute of MIT and Harvard, Cambridge, MA, USA
- Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA
- Department of Medicine, Massachusetts General Hospital, Boston, MA, USA
| | | | | | | | | | - Ian C Kohnle
- Broad Institute of MIT and Harvard, Cambridge, MA, USA
| | - Hans W Pope
- Broad Institute of MIT and Harvard, Cambridge, MA, USA
| | - Austin Ayer
- Broad Institute of MIT and Harvard, Cambridge, MA, USA
| | - Gargi Mishra
- Broad Institute of MIT and Harvard, Cambridge, MA, USA
| | | | - Sarah Y Kim
- Broad Institute of MIT and Harvard, Cambridge, MA, USA
| | | | | | - Dennie T Frederick
- Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA
- Department of Medicine, Massachusetts General Hospital, Boston, MA, USA
- Department of Surgery, Massachusetts General Hospital, Boston, MA, USA
| | - Genevieve M Boland
- Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA
- Department of Medicine, Massachusetts General Hospital, Boston, MA, USA
- Department of Surgery, Massachusetts General Hospital, Boston, MA, USA
| | - W Nicholas Haining
- Broad Institute of MIT and Harvard, Cambridge, MA, USA
- Department of Pediatric Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA
- ArsenalBio, South San Francisco, CA, USA
| | - David E Root
- Broad Institute of MIT and Harvard, Cambridge, MA, USA
| | - John G Doench
- Broad Institute of MIT and Harvard, Cambridge, MA, USA
| | - Nir Hacohen
- Broad Institute of MIT and Harvard, Cambridge, MA, USA
- Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA
- Department of Medicine, Massachusetts General Hospital, Boston, MA, USA
| | - Kathleen B Yates
- Broad Institute of MIT and Harvard, Cambridge, MA, USA.
- Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA.
- Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
| | - Robert T Manguso
- Broad Institute of MIT and Harvard, Cambridge, MA, USA.
- Center for Cancer Research, Massachusetts General Hospital, Boston, MA, USA.
- Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
| |
Collapse
|
3
|
Gadde A, Jha P, Bansal S, Rana A, Bansal D, Yadav D, Jain M, Mahapatra A, Sethi S, Kher V. POS-095 ARE ABO INCOMPATIBLE KIDNEY TRANSPLANT RECIPIENTS AT HIGHER RISK OF INFECTIONS?-A SINGLE CENTER EXPERIENCE. Kidney Int Rep 2022. [DOI: 10.1016/j.ekir.2022.07.113] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
4
|
Dubrot J, Du PP, Lane-Reticker SK, Kessler EA, Muscato AJ, Mehta A, Freeman SS, Allen PM, Olander KE, Ockerman KM, Wolfe CH, Wiesmann F, Knudsen NH, Tsao HW, Iracheta-Vellve A, Schneider EM, Rivera-Rosario AN, Kohnle IC, Pope HW, Ayer A, Mishra G, Zimmer MD, Kim SY, Mahapatra A, Ebrahimi-Nik H, Frederick DT, Boland GM, Haining WN, Root DE, Doench JG, Hacohen N, Yates KB, Manguso RT. Abstract 3610: In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer. Cancer Res 2022. [DOI: 10.1158/1538-7445.am2022-3610] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
The immune system can eliminate tumors, but checkpoints enable tumors to escape immune destruction. Here, we report the systematic identification of immune evasion mechanisms using genome-scale in vivo CRISPR screens in eight murine cancer models treated with immune checkpoint blockade (ICB). We identify and validate previously unreported immune evasion genes and identify key immune inhibitory checkpoints that have a conserved role across several cancer models, such as the non-classical MHC-I molecule Qa-1b/HLA-E, which scores as the top overall sensitizing hit across all screens. Surprisingly, we find that loss of IFNγ signaling by tumor cells sensitizes 6 of 8 cancer models to ICB. While IFN-mediated inflammation has been associated with response to ICB, there have also been reports of ICB-resistance driven by IFN sensing. However, several divergent mechanisms have been proposed to explain the inhibitory effect of tumor IFN sensing, leading to uncertainty about how this key immune signaling pathway is regulating anti-tumor immunity in different contexts. Using in vivo screening data, transcriptional profiling, and genetic interaction studies, we reveal that the immune-inhibitory effects of tumor IFN sensing are the direct result of tumor upregulation of classical and non-classical MHC-I genes. The interferon-MHC-I axis can inhibit anti-tumor immunity through two mechanisms: first, upregulation of classical MHC-I inhibits the cytotoxicity of natural killer cells, which are activated by ICB. Second, IFN-mediated upregulation of Qa-1b directly inhibits cytotoxicity by effector CD8+ T cells via the NKG2A/CD94 receptor, which is induced on CD8+ T cells by ICB. Finally, we show that high interferon-stimulated gene expression in patients is associated with decreased survival in RCC and poor response to ICB in melanoma. Our study establishes a unifying mechanism to explain the inhibitory role of tumor IFN sensing, revealing that IFN-mediated upregulation of classical and non-classical MHC-I inhibitory checkpoints can facilitate immune escape.
Citation Format: Juan Dubrot, Peter P. Du, Sarah Kate Lane-Reticker, Emily A. Kessler, Audrey J. Muscato, Arnav Mehta, Samuel S. Freeman, Peter M. Allen, Kira E. Olander, Kyle M. Ockerman, Clara H. Wolfe, Fabius Wiesmann, Nelson H. Knudsen, Hsiao-Wei Tsao, Arvin Iracheta-Vellve, Emily M. Schneider, Andrea N. Rivera-Rosario, Ian C. Kohnle, Hans W. Pope, Austin Ayer, Gargi Mishra, Margaret D. Zimmer, Sarah Y. Kim, Animesh Mahapatra, Hakimeh Ebrahimi-Nik, Dennie T. Frederick, Genevieve M. Boland, W. Nicholas Haining, David E. Root, John G. Doench, Nir Hacohen, Kathleen B. Yates, Robert T. Manguso. In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 3610.
Collapse
|
5
|
Bansal SB, Gade A, Sinha S, Mahapatra A, Jha P, Sethi SK. HLA Desensitization Based on Results of the Luminex Technique in Kidney Transplant - A Single-center Experience. Indian J Nephrol 2021; 31:454-459. [PMID: 34880555 PMCID: PMC8597796 DOI: 10.4103/ijn.ijn_237_20] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2020] [Revised: 07/19/2020] [Accepted: 09/01/2020] [Indexed: 12/02/2022] Open
Abstract
Background: There is little experience of human leucocyte antigen (HLA) desensitization in India based on the Luminex single-antigen bead (SAB) testing. We retrospectively analyzed our patients, who underwent HLA desensitization based on Luminex SAB results. Method: Between 2014 and 2018, patients with complement-dependent cytotoxicity cross-match (CDC-XM) negativity but flow cytometry crossmatch (FC-XM) positivity were further analyzed with Luminex SAB for donor-specific antibodies (DSAs). A total of 12 patients who had DSA mean fluorescent intensity (MFI) of >1000 and <10,000 were included in the study. Our protocol for desensitization consisted of plasmapheresis (PP) followed by low dose intravenous immunoglobulin (IV IG) 100 mg/kg and induction with antithymocyte globulin (ATG). Patients were taken for transplant when either MFI was <1000 and/or FC-XM was negative. Results: All 12 patients were first transplant and 10 had a history of some sensitizing event; pregnancy in 4, blood transfusions in 4, and both in 2 patients. FC-XM was positive for T-cell in 4, B-cell in 6, and both in 2 patients. On evaluation by Luminex SAB, 6 patients had MFI from 1000 to 2000, and 6 had MFI of >2000. All underwent desensitization successfully. Two patients had an increase in posttransplant DSA titers requiring posttransplant PP. The mean follow-up was 26.6 ± 13.9 months. On follow-up, only one patient developed acute T cell-mediated rejection 1 year after transplant, which responded to pulse steroids. There was no graft or patient loss until the last follow-up. Conclusion: This study shows that HLA desensitization is feasible and successful in the Indian setting if patients are properly selected.
Collapse
Affiliation(s)
- S B Bansal
- Department of Nephrology, Medanta Kidney and Urology Institute, Medanta-Medicity, Gurugram, Haryana, India
| | - A Gade
- Department of Nephrology, Medanta Kidney and Urology Institute, Medanta-Medicity, Gurugram, Haryana, India
| | - S Sinha
- Department of Nephrology, BYL Nair Hospital, Mumbai, Maharashtra, India
| | - A Mahapatra
- Department of Nephrology, Medanta Kidney and Urology Institute, Medanta-Medicity, Gurugram, Haryana, India
| | - P Jha
- Department of Nephrology, Medanta Kidney and Urology Institute, Medanta-Medicity, Gurugram, Haryana, India
| | - S K Sethi
- Department of Nephrology, Medanta Kidney and Urology Institute, Medanta-Medicity, Gurugram, Haryana, India
| |
Collapse
|
6
|
Dubrot J, Lane-Reticker SK, Kessler EA, Ayer A, Mishra G, Wolfe CH, Zimmer MD, Du PP, Mahapatra A, Ockerman KM, Davis TGR, Kohnle IC, Pope HW, Allen PM, Olander KE, Iracheta-Vellve A, Doench JG, Haining WN, Yates KB, Manguso RT. In vivo screens using a selective CRISPR antigen removal lentiviral vector system reveal immune dependencies in renal cell carcinoma. Immunity 2021; 54:571-585.e6. [PMID: 33497609 DOI: 10.1016/j.immuni.2021.01.001] [Citation(s) in RCA: 38] [Impact Index Per Article: 12.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2020] [Revised: 10/20/2020] [Accepted: 12/30/2020] [Indexed: 02/07/2023]
Abstract
CRISPR-Cas9 genome engineering has increased the pace of discovery for immunology and cancer biology, revealing potential therapeutic targets and providing insight into mechanisms underlying resistance to immunotherapy. However, endogenous immune recognition of Cas9 has limited the applicability of CRISPR technologies in vivo. Here, we characterized immune responses against Cas9 and other expressed CRISPR vector components that cause antigen-specific tumor rejection in several mouse cancer models. To avoid unwanted immune recognition, we designed a lentiviral vector system that allowed selective CRISPR antigen removal (SCAR) from tumor cells. The SCAR system reversed immune-mediated rejection of CRISPR-modified tumor cells in vivo and enabled high-throughput genetic screens in previously intractable models. A pooled in vivo screen using SCAR in a CRISPR-antigen-sensitive renal cell carcinoma revealed resistance pathways associated with autophagy and major histocompatibility complex class I (MHC class I) expression. Thus, SCAR presents a resource that enables CRISPR-based studies of tumor-immune interactions and prevents unwanted immune recognition of genetically engineered cells, with implications for clinical applications.
Collapse
Affiliation(s)
- Juan Dubrot
- Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, MA, USA
| | | | - Emily A Kessler
- Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, MA, USA
| | - Austin Ayer
- Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, MA, USA
| | - Gargi Mishra
- Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, MA, USA
| | - Clara H Wolfe
- Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, MA, USA
| | - Margaret D Zimmer
- Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, MA, USA
| | - Peter P Du
- Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, MA, USA
| | - Animesh Mahapatra
- Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, MA, USA
| | - Kyle M Ockerman
- Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, MA, USA
| | - Thomas G R Davis
- Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, MA, USA
| | - Ian C Kohnle
- Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, MA, USA
| | - Hans W Pope
- Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, MA, USA
| | - Peter M Allen
- Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, MA, USA
| | - Kira E Olander
- Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, MA, USA
| | - Arvin Iracheta-Vellve
- Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, MA, USA
| | - John G Doench
- Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, MA, USA
| | - W Nicholas Haining
- Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, MA, USA; Division of Pediatric Hematology and Oncology, Children's Hospital, Boston, MA, USA; Merck Research Laboratories, Boston, MA, USA
| | - Kathleen B Yates
- Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, MA, USA; Center for Cancer Research, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA.
| | - Robert T Manguso
- Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, MA, USA; Center for Cancer Research, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA.
| |
Collapse
|
7
|
Dubrot J, Lane-Reticker SK, Kessler E, Wolfe C, Mahapatra A, Du P, Manguso RT. Abstract 5866: SCAR (Selective CRISPR Antigen Removal) vector system expands cancer immunology discovery with in vivo functional genomics. Cancer Res 2020. [DOI: 10.1158/1538-7445.am2020-5866] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
The ability to make rapid genetic alterations to tumor cells with CRISPR for screens and single-gene studies has been transformative for studying cancer biology. Recently, we and others have used CRISPR in murine tumor models in vivo to identify targets and resistance mechanisms for immunotherapy. However, the use of these techniques in immunocompetent mice is limited by endogenous immune recognition of CRISPR components such as Cas9. Here we report the design of a screening-compatible lentiviral vector system which allows selective CRISPR antigen removal (SCAR) from tumor cells before they are implanted in vivo. The SCAR system enables highly efficient genome engineering and reverses CD8+ T cell-mediated rejection of CRISPR modified tumor cells in vivo. Using this technology, we conducted a pooled, in vivo screen designed to probe tumor-immune interactions in the highly immunogenic CT26 colon carcinoma model and discovered that these tumors require intact interferon signaling to evade immune destruction. The SCAR system enables the study of tumor-immune interactions in any cancer model and can be more broadly applied to generate non-immunogenic lentivirally-engineered cells.
Citation Format: Juan Dubrot, Sarah Kate Lane-Reticker, Emily Kessler, Clara Wolfe, Animesh Mahapatra, Peter Du, Robert T. Manguso. SCAR (Selective CRISPR Antigen Removal) vector system expands cancer immunology discovery with in vivo functional genomics [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 5866.
Collapse
|
8
|
Dubrot J, Manguso RT, Lane-Reticker SK, Ayer A, Kessler E, Wolfe C, Mahapatra A. Abstract B10: Novel CRISPR/Cas9 vectors for in vivo tumor functional genomics. Cancer Immunol Res 2020. [DOI: 10.1158/2326-6074.tumimm19-b10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
During the last decade, there has been notable progress in cancer immunotherapy, including promising clinical success of immune checkpoint inhibitors. Moreover, there is an increasing number of new potential targets for cancer immunotherapy that are currently being developed both as monotherapy or in combination. However, the lack of durable clinical responses due in part to the resistance mechanisms that tumors exhibit in a significant proportion of patients urges novel approaches to find the right therapeutic strategies. The understanding of such tumor evasion mechanisms and the complex interactions that take place in the tumor microenvironment is essential to obtain successful treatments. Functional genomics has emerged as a powerful tool that can help to reveal some of these unknown processes, with CRISPR-Cas9 technology the most prominent example. However, in vivo genetic screens require stable expression of several components that in most cases are not derived from murine cells, which represents a major obstacle in the context of cancer immunology. The inoculation of engineered tumor cell lines in immunocompetent mice results in either tumor rejection or an aberrant response to immunotherapy, making the experiments technically impossible in the first case or providing inconsistent results in the latter. We have designed new vector strategies to overcome the altered immunogenicity of Cas9-expressing tumor cell lines using the Cre-lox system. Expression and effective removal of Cas9 and vector components are monitored using fluorescent reporter proteins. Both genome-editing capacity and normal in vivo behavior of all tested cell lines remain largely unaltered using this novel strategy. This technology represents a major advance for preclinical functional genomics, allowing studies in fully competent animals looking for better combination treatments and resistance mechanism in particular cancer models, and ultimately will help in the design of clinical trials.
Citation Format: Juan Dubrot, Robert T. Manguso, Sarah Kate Lane-Reticker, Austin Ayer, Emily Kessler, Clara Wolfe, Animesh Mahapatra. Novel CRISPR/Cas9 vectors for in vivo tumor functional genomics [abstract]. In: Proceedings of the AACR Special Conference on Tumor Immunology and Immunotherapy; 2019 Nov 17-20; Boston, MA. Philadelphia (PA): AACR; Cancer Immunol Res 2020;8(3 Suppl):Abstract nr B10.
Collapse
|
9
|
Kannan G, Gosukonda R, Mahapatra A. PSVI-41 Application of Artificial Neural Network to Predict Physiological Stress Responses in Goats due to Transportation. J Anim Sci 2018. [DOI: 10.1093/jas/sky404.1021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- G Kannan
- Fort Valley State University,Fort Valley, GA, United States
| | - R Gosukonda
- Fort Valley State University,Fort Valley, GA, United States
| | - A Mahapatra
- Fort Valley State University,Fort Valley, GA, United States
| |
Collapse
|
10
|
Mahapatra A, Tripathy P. Prof. M. Sambasivan (1936–2018). IJNT 2018. [DOI: 10.1055/s-0038-1675323] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Affiliation(s)
- A. Mahapatra
- Former President of NTSI Director, Health Program, Institute of Medical Sciences and Sum Hospital, Bhubaneswar, Odisha, India
| | - Pradipta Tripathy
- Department of Neurosurgery, Vivekananda Hospital, Bhubaneswar, Odisha, India
| |
Collapse
|
11
|
Kumar R, Mahapatra A. Guidelines for Neurosurgery Training Program. IJNS 2018. [DOI: 10.1055/s-0038-1669480] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Affiliation(s)
- Raj Kumar
- Ex-President, Neurological Surgeon's Society of India, Vice Chancellor, Uttar Pradesh University of Medical Sciences, Saifai, Etawah, Uttar Pradesh
| | - A. Mahapatra
- Director (Medical), Sum Hospital, Bhubaneshwar, Orissa
| |
Collapse
|
12
|
Satyarthee G, Chandra P, Mahapatra A. Brain Studded with Innumerable Larger Stones: Starry Sky at Night Appearance: Multiple Calcified Giant Tuberculoma with 15 Years of Follow-up. IJNS 2017. [DOI: 10.1055/s-0037-1601365] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
Abstract
AbstractTuberculosis is rapidly reemerging as a major health problem due to rising incidence of HIV cases across the globe. Central nervous system involvement is rare, but rarely multiple intracerebral granulomas can occur or occasional solitary tuberculoma also develops. The authors report a unique case of 24-year-old woman suffering from pulmonary tuberculosis developed headache and vomiting. Cranial CT scan revealed multiple widespread deposit of intracranial granuloma of sizeable lesion mimicking starry sky at night appearance. Excision of one tuberculoma was done for confirmation of definitive diagnosis, and histopathology was suggestive of tuberculoma. The patient also underwent VP shunt surgery. At last follow-up at 15 years following surgery, she was doing well.
Collapse
Affiliation(s)
- Guru Satyarthee
- Department of Neurosurgery, Neurosciences Centre, AIIMS, New Delhi, India
| | - P. Chandra
- Department of Neurosurgery, Neurosciences Centre, AIIMS, New Delhi, India
| | - A. Mahapatra
- Department of Neurosurgery, Neurosciences Centre, AIIMS, New Delhi, India
| |
Collapse
|
13
|
Lenka D, Mahapatra A. Role of Reconstructive Surgery (RCS) in Improving the Quality of Life of Leprosy Afflicted Persons. Indian J Lepr 2016; 88:7-12. [PMID: 29741820] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/08/2023]
Abstract
Since time immemorial, stigma has been associated with leprosy mainly due to deformity and disability which in turn affects the physical, psychological, social and economical well being of some of the leprosy afflicted persons (LAPs). To prevent and correct deformities Government of India has focused on early diagnosis and appropriate treatment. In addition government has been providing services of Reconstructive Surgery (RCS). RCS corrects the deformity and is expected to help in reducing the stigma in society and reintegrate the affected persons in to society so that they become economically self reliant and carry out their normal livelihood activities without any prejudice. As the stigma has cultural background, this study has.been carried out with to assess the existing stigma level in pre RCS in society in parts of Odisha and compare with that of post RCS. The study was conducted in Sonepur district of Odisha. The sample size is the entire universe of all the 60 patients who had undergone the RCS process, during these the recent years. The methods adopted for data collection were the tools like questionnaire schedules, interview, observation, FGD and in depth case studies. Almost 86% of these Leprosy afflicted persons (LAPs) were very satisfied due to improvement in acceptance by their family, friend, relatives and society after surgery because of the correction of deformity by RCS as it enabled them to get back into normal life. The economical status improved in 8/60 (13%) after RCS, some becoming capable of earning more than Rs. 10,000/- per month after RCS. To conclude, in this settings of Sonepur (Odisha). RCS appeared to help the LAPs in improving their social acceptance thereby reducing stigma and also improving their economic status thus empowering them to lead their life as a normal human beings. There is need to enlarge and expand these studies to other parts of state/region so that the link with beliefs, type of disabilities and also type of surgery could be better understood and the knowledge generated could be applied to get optimum results.
Collapse
|
14
|
Bhatt M, Sarangi G, Paty BP, Mohapatra D, Chayani N, Mahapatra A, Das P, Sahoo D. Biofilm as a virulence marker in Candida species in Nosocomial blood stream infection and its correlation with antifungal resistance. Indian J Med Microbiol 2015; 33 Suppl:112-4. [PMID: 25657126 DOI: 10.4103/0255-0857.150909] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
Nosocomial blood stream infections (BSI) due to fungi especially Candida is increasing steadily. A two year prospective study was conducted in the S.C.B. Medical College with an aim to evaluate the species distribution, antifungal susceptibility and biofilm formation of Candida spp. isolated from nosocomial BSIs. 34 Candida spp. were isolated from 359 blood cultures. Antifungal susceptibility was performed by microbroth dilution technique and both visual and spectrophotometric method were used for biofilm detection. C. tropicalis was the common spp. isolated followed by C. parapsilosis and others. Most (92%) of the isolates were susceptible to Amphoterecin-B and highest resistance was observed against Flucytosine (37%) and Fluconazole(35%). Biofilm production and antifungal resistance was observed more in nonalbicans Candida spp.
Collapse
Affiliation(s)
- M Bhatt
- Department of Microbiology, Shri Ramachandra Bhanj Medical College and Hospital, Cuttack, India
| | | | | | | | | | | | | | | |
Collapse
|
15
|
Bertozzi AI, Munzer C, Fouyssac F, Andre N, Boetto S, Leblond P, Bourdeaut F, Dufour C, Deshpande RK, Bhat KG, Mahalingam S, Muscat A, Cain J, Ferguson M, Popovski D, Algar E, Rossello FJ, Jayasekara S, Watkins DN, Hodge J, Ashley D, Hishii M, Saito M, Arai H, Han ZY, Richer W, Lucchesi C, Freneaux P, Nicolas A, Grison C, Pierron G, Delattre O, Bourdeaut F, Epari S, TS N, Gupta T, Chinnaswamy G, Sastri JG, Shetty P, Moiyadi A, Jalali R, Fay-McClymont T, Johnston D, Janzen L, Guger S, Scheinemann K, Fleming A, Fryer C, Hukin J, Mabbott D, Huang A, Bouffet E, Lafay-Cousin L, Kawamura A, Yamamoto K, Nagashima T, Bartelheim K, Benesch M, Buchner J, Gerss J, Hasselblatt M, Kortmann RD, Fleischack G, Quiroga E, Reinhard H, Schneppenheim R, Seeringer A, Siebert R, Timmermann B, Warmuth-Metz M, Schmid I, Fruhwald MC, Fruhwald MC, Bartelheim K, Seeringer A, Kerl K, Kortmann RD, Warmuth-Metz M, Hasselblatt M, Schneppenheim R, Siebert R, Klingebiel T, Al-Kofide A, Khafaga Y, Al-Hindi H, Dababo M, Ul-Haq A, Anas M, Barria MG, Siddiqui K, Hassounah M, Ayas M, Al-Shail E, Hasselblatt M, Jeibmann A, Eikmeier K, Linge A, Johann P, Koos B, Bartelheim K, Kool M, Pfister SM, Fruhwald MC, Paulus W, Hasselblatt M, Schuller U, Junckerstorff R, Rosenblum MK, Alassiri AH, Rossi S, Bartelheim K, Schmid I, Gottardo N, Toledano H, Viscardi E, Witkowski L, Nagel I, Oyen F, Foulkes WD, Paulus W, Siebert R, Schneppenheim R, Fruhwald MC, Schrey D, Malietzis G, Chi S, Dufour C, Lafay-Cousin L, Marshall L, Carceller F, Moreno L, Zacharoulis S, Bhardwaj R, Chakravadhanula M, Ozals V, Hampton C, Metpally R, Grillner P, Asmundsson J, Gustavsson B, Holm S, Johann PD, Korshunov A, Ryzhova M, Kerl K, Milde T, Witt O, Jones DTW, Hovestadt V, Gajjar A, Hasselblatt M, Fruhwald M, Pfister S, Kool M, Finetti M, Pons ADC, Selby M, Smith A, Crosier S, Wood J, Skalkoyannis B, Bailey S, Clifford S, Williamson D, Seeringer A, Bartelheim K, Kerl K, Hasselblatt M, Rutkowski S, Timmermann B, Kortmann RD, Schneppenheim R, Warmuth-Metz M, Gerss J, Siebert R, Graf N, Boos J, Nysom K, Fruhwald MC, Kerl K, Moreno N, Holsten T, Ahlfeld J, Mertins J, Hotfilder M, Kool M, Bartelheim K, Schleicher S, Handgretinger R, Fruhwald M, Meisterernst M, Kerl K, Schmidt C, Ahlfeld J, Moreno N, Dittmar S, Pfister S, Fruhwald M, Kool M, Meisterernst M, Schuller U, Chan GCF, Shing MMK, Yuen HL, Li RCH, Ling SL, Slavc I, Peyrl A, Chocholous M, Azizi A, Czech T, Dieckmann K, Haberler C, Leiss U, Gotti G, Biassoni V, Schiavello E, Spreafico F, Pecori E, Gandola L, Massimino M, Mertins J, Kornelius K, Moreno N, Holsten T, Fruhwald M, Kool M, Meisterernst M, Yano H, Nakayama N, Ohe N, Ozeki M, Kanda K, Kimura T, Hori T, Fukao T, Iwama T, Weil AG, Diaz A, Gernsback J, Bhatia S, Ragheb J, Niazi T, Khatib Z, Kerl K, Holsten T, Moreno N, Zoghbi A, Meisterernst AM, Birks D, Griesinger A, Amani V, Donson A, Posner R, Dunham C, Kleinschmidt-DeMasters BK, Handler M, Vibhakar R, Foreman N, Bhardwaj R, Ozals V, Hampton C, Zhou L, Catchpoole D, Chakravadhanula M, Kakkar A, Biswas A, Suri V, Sharma M, Kale S, Mahapatra A, Sarkar C, Torchia J, Picard D, Ho KC, Khuong-Quang DA, Louterneau L, Bourgey M, Chan T, Golbourn B, Cousin LL, Taylor MD, Dirks P, Rutka JT, Bouffet E, Hawkins C, Majewski J, Kim SK, Jabado N, Huang A, Chang JHC, Confer M, Chang A, Goldman S, Dunn M, Hartsell W. ATYPICAL TERATOID RHABDOID TUMOUR. Neuro Oncol 2014. [DOI: 10.1093/neuonc/nou065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
16
|
Mohapatra RK, Dash M, Mishra UK, Mahapatra A, Dash DC. Synthesis, Spectral Characterization, and Fungicidal Activity of Transition Metal Complexes With Benzimidazolyl-2-hydrazones of Glyoxal, Diacetyl, and Benzil. ACTA ACUST UNITED AC 2013. [DOI: 10.1080/15533174.2013.776592] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Affiliation(s)
- R. K. Mohapatra
- a Department of Chemistry , Govt. College of Engineering , Keonjhar , Odisha , India
| | - M. Dash
- a Department of Chemistry , Govt. College of Engineering , Keonjhar , Odisha , India
| | - U. K. Mishra
- b School of Chemistry , Sambalpur University , Jyoti Vihar, Burla, Sambalpur , Odisha , India
| | - A. Mahapatra
- b School of Chemistry , Sambalpur University , Jyoti Vihar, Burla, Sambalpur , Odisha , India
| | - D. C. Dash
- b School of Chemistry , Sambalpur University , Jyoti Vihar, Burla, Sambalpur , Odisha , India
| |
Collapse
|
17
|
Ahmed I, Biswas A, Krishnamurthy S, Julka P, Rath G, Back M, Huang D, Gzell C, Chen J, Kastelan M, Gaur P, Wheeler H, Badiyan SN, Robinson CG, Simpson JR, Tran DD, Rich KM, Dowling JL, Chicoine MR, Leuthardt EC, Kim AH, Huang J, Michaelsen SR, Christensen IJ, Grunnet K, Stockhausen MT, Broholm H, Kosteljanetz M, Poulsen HS, Tieu M, Lovblom E, Macnamara M, Mason W, Rodin D, Tai E, Ubhi K, Laperriere N, Millar BA, Menard C, Perkins B, Chung C, Clarke J, Molinaro A, Phillips J, Butowski N, Chang S, Perry A, Costello J, DeSilva A, Rabbitt J, Prados M, Cohen AL, Anker C, Shrieve D, Hall B, Salzman K, Jensen R, Colman H, Farber O, Weinberg U, Palti Y, Fisher B, Chen H, Macdonald D, Lesser G, Coons S, Brachman D, Ryu S, Werner-Wasik M, Bahary JP, Chakravarti A, Mehta M, Gupta T, Nair V, Epari S, Godasastri J, Moiyadi A, Shetty P, Juvekar S, Jalali R, Herrlinger U, Schafer N, Steinbach J, Weyerbrock A, Hau P, Goldbrunner R, Kohnen R, Urbach H, Stummer W, Glas M, Houillier C, Ghesquieres H, Chabrot C, Soussain C, Ahle G, Choquet S, Faurie P, Bay JO, Vargaftig J, Gaultier C, Nicolas-Virelizier E, Hoang-Xuan K, Iskanderani O, Izar F, Benouaich-Amiel A, Filleron T, Moyal E, Iweha C, Jain S, Melian E, Sethi A, Albain K, Shafer D, Emami B, Kong XT, Green S, Filka E, Green R, Yong W, Nghiemphu P, Cloughesy T, Lai A, Mallick S, Biswas A, Roy S, Purkait S, Gupta S, Julka PK, Rath GK, Marosi C, Thaler J, Ay C, Kaider A, Reitter EM, Haselbock J, Preusser M, Flechl B, Zielinski C, Pabinger I, Miyatake SI, Furuse M, Miyata T, Yoritsune E, Kawabata S, Kuroiwa T, Muragaki Y, Maruyama T, Iseki H, Akimoto J, Ikuta S, Nitta M, Maebayashi K, Saito T, Okada Y, Kaneko S, Matsumura A, Kuroiwa T, Karasawa K, Nakazato Y, Kayama T, Nabors LB, Fink KL, Mikkelsen T, Grujicic D, Tarnawski R, Nam DH, Mazurkiewicz M, Salacz M, Ashby L, Thurzo L, Zagonel V, Depenni R, Perry JR, Henslee-Downey J, Picard M, Reardon DA, Nambudiri N, Nayak L, LaFrankie D, Wen P, Ney D, Carlson J, Damek D, Blatchford P, Gaspar L, Kavanagh B, Waziri A, Lillehei K, Reddy K, Chen C, Rashed I, Melian E, Sethi A, Barton K, Anderson D, Prabhu V, Rusch R, Belongia M, Maheshwari M, Firat S, Schiff D, Desjardins A, Cloughesy T, Mikkelsen T, Glantz M, Chamberlain M, Reardon DA, Wen P, Shapiro W, Gopal S, Judy K, Patel S, Mahapatra A, Shan J, Gupta D, Shih K, Bacha JA, Brown D, Garner WJ, Steino A, Schwart R, Kanekal S, Li M, Lopez L, Burris HA, Soderberg-Naucler C, Rahbar A, Stragliotto G, Song AJ, Kumar AMS, Murphy ES, Tekautz T, Suh JH, Recinos V, Chao ST, Spoor J, Korami K, Kloezeman J, Balvers R, Dirven C, Lamfers M, Leenstra S, Sumrall A, Haggstrom D, Crimaldi A, Symanowski J, Giglio P, Asher A, Burri S, Sunkersett G, Khatib Z, Prajapati CM, Magalona EE, Mariano M, Sih IM, Torcuator R, Taal W, Oosterkamp H, Walenkamp A, Beerenpoot L, Hanse M, Buter J, Honkoop A, Boerman D, de Vos F, Jansen R, van der Berkmortel F, Brandsma D, Enting R, Kros J, Bromberg J, van Heuvel I, Smits M, van der Holt R, Vernhout R, van den Bent M, Weinberg U, Farber O, Palti Y, Wick W, Suarez C, Rodon J, Desjardins A, Forsyth P, Gueorguieva I, Cleverly A, Burkholder T, Desaiah D, Lahn M, Zach L, Guez D, Last D, Daniels D, Nissim O, Grober Y, Hoffmann C, Nass D, Talianski A, Spiegelmann R, Cohen Z, Mardor Y. MEDICAL RADIATION THERAPIES. Neuro Oncol 2013; 15:iii75-iii84. [PMCID: PMC3823894 DOI: 10.1093/neuonc/not179] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 09/21/2023] Open
|
18
|
Mahapatra A, Mishra BG, Hota G. Electrospun Fe2O3-Al2O3 nanocomposite fibers as efficient adsorbent for removal of heavy metal ions from aqueous solution. J Hazard Mater 2013; 258-259:116-23. [PMID: 23708454 DOI: 10.1016/j.jhazmat.2013.04.045] [Citation(s) in RCA: 78] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/29/2013] [Revised: 04/15/2013] [Accepted: 04/29/2013] [Indexed: 05/06/2023]
Abstract
In this study, Iron oxide-alumina mixed nanocomposite fiber was prepared by electrospinning method and its performance was evaluated as a heavy metal ion adsorbent. Here boehmite nanoparticle was synthesized by sol-gel method and was impregnated in PVP-iron acetylacetonate solution in a ratio of 1:1:2. These boehmite impregnated polymer solution was electrospun to form nanocomposite polymer fiber. The electrospun nanofiber was sintered at 1000°C for converting it to pure oxide form for further application as adsorbent. Iron oxide-alumina mixed nanocomposite fiber was characterized by UV-vis-DRS, IR, SEM-EDX, TEM, BET and TGA-DTA analytical techniques. Batch adsorption experiments were carried out to study the sorption behavior of Cu(2+), Pb(2+), Ni(2+) and Hg(2+) ions as a function of initial concentration, contact time and pH. The removal percentage was in the order of Cu(2+)<Pb(2+)<Ni(2+)<Hg(2+). The maximum sorption capacities by applying the Langmuir equation were found to be 4.98 mg/g for Cu(2+), 32.36 mg/g for Ni(2+), 23.75 mg/g for Pb(2+) and 63.69 mg/g for Hg(2+) ions. The regeneration studies of mixed nanocomposite adsorbents were also reported here.
Collapse
Affiliation(s)
- A Mahapatra
- Department of Chemistry, NIT Rourkela, Orissa, India
| | | | | |
Collapse
|
19
|
Mahapatra A, Mishra BG, Hota G. Studies on Electrospun Alumina Nanofibers for the Removal of Chromium(VI) and Fluoride Toxic Ions from an Aqueous System. Ind Eng Chem Res 2013. [DOI: 10.1021/ie301586j] [Citation(s) in RCA: 78] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Affiliation(s)
- A. Mahapatra
- Department of Chemistry, NIT Rourkela, Orissa, India 769008
| | - B. G. Mishra
- Department of Chemistry, NIT Rourkela, Orissa, India 769008
| | - G. Hota
- Department of Chemistry, NIT Rourkela, Orissa, India 769008
| |
Collapse
|
20
|
Park CK, Kim YH, Kim JW, Kim TM, Choi SH, Kim YJ, Choi BS, Lee SH, Kim CY, Kim IH, Lee DZ, Kheder A, Forbes M, Craven I, Hadjivassiliou M, Shonka NA, Kessinger A, Aizenberg MR, Weller M, Meisner C, Platten M, Simon M, Nikkhah G, Papsdorf K, Sabel M, Braun C, Reifenberger G, Wick W, Alexandru D, Haghighi B, Muhonen MG, Chamberlain MC, Sumrall AL, Burri S, Brick W, Asher A, Murillo-Medina K, Guerrero-Maldonado A, Ramiro AJ, Cervantes-Sanchez G, Erazo-Valle-Solis AA, Garcia-Navarro V, Sperduto PW, Shanley R, Luo X, Kased N, Sneed PK, Roberge D, Chao S, Weil R, Suh J, Bhatt A, Jensen A, Brown PD, Shih H, Kirkpatrick J, Gaspar LE, Fiveash J, Chiang V, Knisely J, Sperduto CM, Lin N, Mehta MP, Anderson MD, Raghunathan A, Aldape KD, Fuller GN, Gilbert MR, Robins HI, Wang M, Gilbert MR, Chakravarti A, Grimm S, Penas-Prado M, Chaudhary R, Anderson PJ, Elinzano H, Gilbert RA, Mehta M, Aoki T, Ueba T, Arakawa Y, Miyatake SI, Tsukahara T, Miyamoto S, Nozaki K, Taki W, Matsutani M, Shakur SF, Bit-Ivan E, Watkin WG, Farhat HI, Merrell RT, Zwinkels H, Dorr J, Kloet A, Taphoorn MJ, Vecht CJ, Bogdahn U, Stockhammer G, Mahapatra A, Hau P, Schuknecht B, van den Bent M, Heinrichs H, Yust-Katz S, Liu V, Sanghee K, Groves M, Puduvalli V, Levin V, Conrad C, Colman H, Hsu S, Yung AW, Gilbert MR, Kunz M, Armbruster L, Thon N, Jansen N, Lutz J, Herms J, Egensperger R, Eigenbrod S, Kretzschmar H, La CF, Tonn JC, Kreth FW, Brandes AA, Franceschi E, Agati R, Poggi R, Dall'Occa P, Bartolotti M, Di Battista M, Marucci G, Girardi F, Ermani M, Sherman W, Raizer J, Grimm S, Ruckser R, Tatzreiter G, Pfisterer W, Oberhauser G, Honigschnabel S, Aboul-Enein F, Ausch C, Kitzweger E, Hruby W, Sebesta C, Green RM, Woyshner EA, Suchorska B, Jansen NL, Janssen H, Kretzschmar H, Simon M, Hentschel B, Poepperl G, Kreth FW, Linn J, LaFougere C, Weller M, Tonn JC, Suchorska B, Jansen NL, Graute V, Eigenbrod S, Bartenstein P, Kreth FW, LaFougere C, Tonn JC, Hassanzadeh B, Tohidi V, Levacic D, Landolfi JC, Singer S, DeBraganca K, Omuro A, Grommes C, Omar AI, Jalan P, Pandav V, Bekker S, Fuente MIDL, Kaley T, Zhao S, Chen X, Soffietti R, Magistrello M, Bertero L, Bosa C, Crasto SG, Garbossa D, Lolli I, Trevisan E, Ruda R, Ruda R, Bertero L, Bosa C, Trevisan E, Pace A, Carapella C, Dealis C, Caroli M, Faedi M, Bomprezzi C, Thomas AA, Dalmau J, Gresa-Arribas N, Fadul CE, Kumthekar PU, Raizer J, Grimm S, Herrada J, Antony N, Richards M, Gupta A, Landeros M, Arango C, Campos-Gines AF, Friedman P, Wilson H, Streeter JC, Cohen A, Gilreath J, Sageser D, Ye X, Bell SD, McGregor J, Bourekas E, Cavaliere R, Newton H, Sul J, Odia Y, Zhang W, Shih J, Butman JA, Hammoud D, Kreisl TN, Iwamoto F, Fine HA, Berriel LG, Santos FN, Levy AC, Fanelli MF, Chinen LT, da Costa AA, Bourekas E, Wayne Slone H, Bell SD, McGregor J, Bokstein F, Blumenthal DT, Shpigel S, Phishniak L, Yust-Katz S, Garciarena P, Liue D, Yuan Y, Groves MD, Wong ET, Villano JL, Engelhard HH, Ram Z, Sahebjam S, Millar BA, Sahgal A, Laperriere N, Mason W, Levin VA, Hess KR, Choucair AK, Flynn PJ, Jaeckle KA, Kyritsis AP, Yung WKA, Prados MD, Bruner JM, Ictech S, Nghiemphu PL, Lai A, Green RM, Cloughesy TF, Zaky W, Gilles F, Grimm J, Bluml S, Dhall G, Rosser T, Randolph L, Wong K, Olch A, Krieger M, Finlay J, Capellades J, Verger E, Medrano S, Gonzalez S, Gil M, Reynes G, Ribalta T, Gallego O, Segura PP, Balana C, Gwak HS, Joo J, Kim S, Yoo H, Shin SH, Han JY, Kim HT, Yun T, Lee JS, Lee SH, Kim W, Vogelbaum MA, Wang M, Peereboom DM, Macdonald DR, Giannini C, Suh JH, Jenkins RB, Laack NN, Brackman DG, Shrieve DC, Souhami L, Mehta MP, Leibetseder A, Wohrer A, Ackerl M, Flechl B, Sax C, Spiegl-Kreinecker S, Pichler J, Widhalm G, Dieckmann K, Preusser M, Marosi C, Sebastian C, Alejandro M, Bernadette C, Naomi A, Kavan P, Sahebjam S, Garoufalis E, Guiot MC, Muanza T, Del Maestro R, Petrecca K, Sharma R, Curry R, Joyce J, Rosenblum M, Jaffe E, Matasar M, Lin O, Fisher R, Omuro A, Yin C, Iwamoto FM, Fraum TJ, Nayak L, Diamond EL, DeAngelis LM, Pentsova E, Vera-Bolanos E, Gilbert MR, Aldape K, Necesito-Reyes MJ, Fouladi M, Gajjar A, Goldman S, Metellus P, Mikkelsen T, Omuro A, Packer R, Partap S, Pollack IF, Prados M, Ian Robins H, Soffietti R, Wu J, Armstrong TS, Nakada M, Hayashi Y, Miyashita K, Kinoshita M, Furuta T, Sabit H, Kita D, Hayashi Y, Uchiyam N, Kawakami K, Minamoto T, Hamada JI, Diamond EL, Rosenblum M, Heaney M, Carrasquillo J, Krauthammer A, Nolan C, Kaley TJ, Gil MJ, Fuster J, Balana C, Benavides M, Mesia C, Etxaniz O, Canellas J, Perez-Martin X, Hunter K, Johnston SK, Bridge CA, Rockne RC, Guyman L, Baldock AL, Rockhill JK, Mrugala MM, Beard BC, Adair JE, Kiem HP, Swanson KR, Ranjan T, Desjardins A, Peters KB, Alderson L, Kirkpatrick J, Herndon J, Bailey L, Sampson J, Friedman AH, Friedman H, Vredenburgh JJ, Theeler BJ, Ellezam B, Melguizo-Gavilanes I, Shonka NA, Bruner JM, Puduvalli VK, Taylor JW, Flanagan E, O'Neill B, Seigal T, Omuro A, DeAngelis L, Baerhing J, Hoang-Xuan K, Chamberlain M, Batchelor T, Nishikawa R, Pinto F, Blay JY, Korfel A, Schiff D, Fu BD, Kong XT, Bota D, Omuro A, Beal K, Ivy P, Gutin P, Wu N, Kaley T, Karimi S, DeAngelis L, Pentsova H, Nolan C, Grommes C, Chan T, Mathew R, Droms L, Shimizu F, Tabar V, Grossman S, Yovino S, Campian J, Wild A, Herman J, Brock M, Balmanoukian A, Ye X, Portnow J, Badie B, Synold T, Lacey S, D'Apuzzo M, Frankel P, Chen M, Aboody K, Letarte N, Gabay MP, Bressler LR, Stachnik JM, Villano JL, Jaeckle KA, Anderson SK, Willson A, Moreno-Aspitia A, Colon-Otero G, Patel T, Perez E, Peters KB, Reardon DA, Vredenburgh JJ, Desjardins A, Herndon JE, Coan A, McSherry F, Lipp E, Brickhouse A, Massey W, Friedman HS, Alderson LM, Desjardins A, Ranjan T, Peters KB, Friedman HS, Vredenburgh JJ, Ranjan T, Desjardins A, Peters KB, Alderson L, Kirkpatrick J, Herndon J, Bailey L, Sampson J, Friedman AH, Friedman H, Vredenburgh J, Welch MR, Omuro A, Grommes C, Westphal M, Bach F, Reuter D, Ronellenfitsch M, Steinbach J, Pietsch T, Connelly J, Hamza MA, Puduvalli V, Neal ML, Trister AD, Ahn S, Bridge C, Lange J, Baldock A, Rockne R, Mrugala M, Rockhill JK, Lai A, Cloughesy T, Swanson KR, Neuwelt AJ, Nguyen TM, Tyson RM, Nasseri M, Neuwelt EA, Bubalo JS, Barnes PD, Phuphanich S, Hu J, Rudnick J, Chu R, Yu J, Naruse R, Ljubimova J, Sanchez C, Guevarra A, Naor R, Black K, Mahta A, Bhavsar TM, Herath K, Huang C, McClain J, Rizzo K, Sheehan J, Chamberlain M, Glantz M, McClain J, Glantz MJ, Zoccoli C, Nicholas MK, Xie T, White D, Liker S, Gajewski T, Selfridge J, Piccioni DE, Zurayk M, Mody R, Quan J, Li S, Chen W, Chou A, Liau L, Green R, Cloughesy T, Lai A, Gomez-Molinar V, Ruiz-Gonzalez S, Valdez-Vazquez R, Arrieta O, Stenner JI. CLIN-NEURO/MEDICAL ONCOLOGY. Neuro Oncol 2012. [DOI: 10.1093/neuonc/nos229] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
21
|
Manohar R, Eranezhath S, Mahapatra A, Manohar R S. P05.15. Online indexing service for research articles published on Ayurveda. Altern Ther Health Med 2012. [PMCID: PMC3373922 DOI: 10.1186/1472-6882-12-s1-p375] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
22
|
|
23
|
Borkar S, Singh M, Mahapatra A. Spinal Cerebrospinal Fluid Drainage for Prevention of Vasospasm in Aneurysmal Subarachnoid Hemorrhage: A Prospective Randomized Controlled Study. Skull Base Surg 2012. [DOI: 10.1055/s-0032-1314291] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
24
|
Mohapatra R, Ghosh S, Naik P, Mishra S, Mahapatra A, Dash D. Synthesis and Characterization of Homo Binuclear Macrocyclic Complexes of UO 2(VI), Th(IV), ZrO(IV) and VO(IV) with Schiff-Bases Derived from Ethylene diamine/Orthophenylene Diamine, Benzilmonohydrazone and Acetyl Acetone. Journal of the Korean Chemical Society 2012. [DOI: 10.5012/jkcs.2012.56.1.062] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
25
|
Mohapatra R, Mishra U, Mishra S, Mahapatra A, Dash D. Synthesis and Characterization of Transition Metal Complexes with Benzimidazolyl-2-hydrazones of o-anisaldehyde and Furfural. Journal of the Korean Chemical Society 2011. [DOI: 10.5012/jkcs.2011.55.6.926] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
26
|
Mahapatra A, Garg N, Nayak BP, Mishra BG, Hota G. Studies on the synthesis of electrospun PAN-Ag composite nanofibers for antibacterial application. J Appl Polym Sci 2011. [DOI: 10.1002/app.35076] [Citation(s) in RCA: 52] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
27
|
Dash D, Mahapatra A, Naik P, Mohapatra R, Naik S. Synthesis and Characterization of Homobinuclear Complexes of UO2(VI), ZrO(IV) and Th(IV) ions with 3-Benzylidine/Furfurylidine/(Pyridyl/Thienyl-2'-methylene) imino-5-p-sulphonamido phenyl azo-2-thiohydantoins. Journal of the Korean Chemical Society 2011. [DOI: 10.5012/jkcs.2011.55.3.412] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
28
|
|
29
|
Rauth G, Mahapatra A, Sinha C. Kinetics and Mechanism of Nucleophilic Substitution of Dichloro-{1-benzyl-2-(arylazo)imidazole}palladium(II) by Pyridine Bases. ACTA ACUST UNITED AC 2010. [DOI: 10.1080/1028662021000003856] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Affiliation(s)
- G.K. Rauth
- a Department of Chemistry , The University of Burdwan , Burdwan , 713104 , India
| | - A. Mahapatra
- b Department of Chemistry , The University of Kalyani , Kalyani , 741235 , India
| | - C. Sinha
- a Department of Chemistry , The University of Burdwan , Burdwan , 713104 , India
| |
Collapse
|
30
|
Furst DE, Venkatraman MM, Krishna Swamy BG, McGann M, Booth-LaForce C, Ram Manohar P, Sarin R, Mahapatra A, Krishna Kumar PR. Well controlled, double-blind, placebo-controlled trials of classical Ayurvedic treatment are possible in rheumatoid arthritis. Ann Rheum Dis 2010; 70:392-3. [DOI: 10.1136/ard.2010.136226] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
31
|
|
32
|
Bogdahn U, Mahapatra A, Olyushin VE, Mouli C, Parfenov VE, Stockhammer G, Ludwig S, Wuerth G, Heinrichs H, Schlingensiepen K. A phase IIb actively controlled study with the TGF-beta-2 inhibitor AP 12009 for recurrent or refractory anaplastic astrocytoma. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.2025] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
2025 Background: The TGF-β2 antisense phosphorothioate oligonucleotide inhibitor AP 12009 is a targeted anti-tumor therapy for TGF-β2 overexpressing tumors. In three Phase I/II dose escalation studies complete and long-lasting responses were observed in patients with recurrent or refractory anaplastic astrocytoma. Methods: The Phase IIb actively controlled dose finding study G004 is an open-label, randomized trial in adult patients with recurrent or refractory high-grade glioma (HGG) confirmed by central histopathology. 145 patients were randomized into three groups: Low dose AP 12009 (10 μM), high dose AP 12009 (80 μM), or standard chemotherapy, i.e. TMZ (or PCV if TMZ had already failed). Study objective was to compare the efficacy and safety of the three treatment groups. AP 12009 was applied locoregionally by convection- enhanced delivery (CED) with up to 11 treatment cycles (7-day-on, 7-day-off / per cycle). Results: Here we report on patients with recurrent anaplastic astrocytoma (AA, Grade III; GBM patients see separate abstract). 39 AA patients were treated, 12 pts received AP 12009 10 μM (AP-10), 15 pts 80 μM (AP-80), and 12 pts standard chemotherapy (10 pts TMZ, 2 pts PCV). Preliminary safety data reveal no SAEs related to the study drug in the AP-10 and AP-80 groups vs. one in the control group. Survival rates were higher in both AP 12009 groups compared to the chemotherapy group (see table ). In both AP 12009 groups mOS has not yet been reached. Overall survival at present is 28.6 months for the AP-10 group, 24.2 months for the AP-80 group, and 20.2 months for the control group. Dose finding was achieved, as efficacy and safety results for the AP-10 group were superior to those of the AP-80 group (see table ). Conclusion: AP 12009 revealed a positive benefit-risk profile and demonstrated excellent potential as monotherapy for the treatment of recurrent or refractory AA patients, especially for the AP 12009 10 μM group. [Table: see text] [Table: see text]
Collapse
Affiliation(s)
- U. Bogdahn
- University of Regensburg, Regensburg, Germany; All India Institute of Medical Sciences, New Delhi, India; Polenov Neurosurgery Research Institute, St. Petersburg, Russian Federation; Nat. Institute of Mental Health and Neurosciences, Bangalore, India; Military Medical Academy, St. Petersburg, Russian Federation; University Hospital Innsbruck, Innsbruck, Austria; Antisense Pharma GmbH, Regensburg, Germany
| | - A. Mahapatra
- University of Regensburg, Regensburg, Germany; All India Institute of Medical Sciences, New Delhi, India; Polenov Neurosurgery Research Institute, St. Petersburg, Russian Federation; Nat. Institute of Mental Health and Neurosciences, Bangalore, India; Military Medical Academy, St. Petersburg, Russian Federation; University Hospital Innsbruck, Innsbruck, Austria; Antisense Pharma GmbH, Regensburg, Germany
| | - V. E. Olyushin
- University of Regensburg, Regensburg, Germany; All India Institute of Medical Sciences, New Delhi, India; Polenov Neurosurgery Research Institute, St. Petersburg, Russian Federation; Nat. Institute of Mental Health and Neurosciences, Bangalore, India; Military Medical Academy, St. Petersburg, Russian Federation; University Hospital Innsbruck, Innsbruck, Austria; Antisense Pharma GmbH, Regensburg, Germany
| | - C. Mouli
- University of Regensburg, Regensburg, Germany; All India Institute of Medical Sciences, New Delhi, India; Polenov Neurosurgery Research Institute, St. Petersburg, Russian Federation; Nat. Institute of Mental Health and Neurosciences, Bangalore, India; Military Medical Academy, St. Petersburg, Russian Federation; University Hospital Innsbruck, Innsbruck, Austria; Antisense Pharma GmbH, Regensburg, Germany
| | - V. E. Parfenov
- University of Regensburg, Regensburg, Germany; All India Institute of Medical Sciences, New Delhi, India; Polenov Neurosurgery Research Institute, St. Petersburg, Russian Federation; Nat. Institute of Mental Health and Neurosciences, Bangalore, India; Military Medical Academy, St. Petersburg, Russian Federation; University Hospital Innsbruck, Innsbruck, Austria; Antisense Pharma GmbH, Regensburg, Germany
| | - G. Stockhammer
- University of Regensburg, Regensburg, Germany; All India Institute of Medical Sciences, New Delhi, India; Polenov Neurosurgery Research Institute, St. Petersburg, Russian Federation; Nat. Institute of Mental Health and Neurosciences, Bangalore, India; Military Medical Academy, St. Petersburg, Russian Federation; University Hospital Innsbruck, Innsbruck, Austria; Antisense Pharma GmbH, Regensburg, Germany
| | - S. Ludwig
- University of Regensburg, Regensburg, Germany; All India Institute of Medical Sciences, New Delhi, India; Polenov Neurosurgery Research Institute, St. Petersburg, Russian Federation; Nat. Institute of Mental Health and Neurosciences, Bangalore, India; Military Medical Academy, St. Petersburg, Russian Federation; University Hospital Innsbruck, Innsbruck, Austria; Antisense Pharma GmbH, Regensburg, Germany
| | - G. Wuerth
- University of Regensburg, Regensburg, Germany; All India Institute of Medical Sciences, New Delhi, India; Polenov Neurosurgery Research Institute, St. Petersburg, Russian Federation; Nat. Institute of Mental Health and Neurosciences, Bangalore, India; Military Medical Academy, St. Petersburg, Russian Federation; University Hospital Innsbruck, Innsbruck, Austria; Antisense Pharma GmbH, Regensburg, Germany
| | - H. Heinrichs
- University of Regensburg, Regensburg, Germany; All India Institute of Medical Sciences, New Delhi, India; Polenov Neurosurgery Research Institute, St. Petersburg, Russian Federation; Nat. Institute of Mental Health and Neurosciences, Bangalore, India; Military Medical Academy, St. Petersburg, Russian Federation; University Hospital Innsbruck, Innsbruck, Austria; Antisense Pharma GmbH, Regensburg, Germany
| | - K. Schlingensiepen
- University of Regensburg, Regensburg, Germany; All India Institute of Medical Sciences, New Delhi, India; Polenov Neurosurgery Research Institute, St. Petersburg, Russian Federation; Nat. Institute of Mental Health and Neurosciences, Bangalore, India; Military Medical Academy, St. Petersburg, Russian Federation; University Hospital Innsbruck, Innsbruck, Austria; Antisense Pharma GmbH, Regensburg, Germany
| |
Collapse
|
33
|
Hau P, Bogdahn U, Olyushin VE, Mahapatra A, Parfenov VE, Venkataramana K, Ludwig S, Jachimczak P, Heinrichs H, Schlingensiepen K. Results of a phase IIb study in recurrent or refractory glioblastoma patients with the TGF-beta-2 inhibitor AP 12009. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.12521] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
12521 Background: The antisense phosphorothioate oligonucleotide compound AP 12009 targets TGF-beta2. Since TMZ is now used in the adjuvant setting in GBM there is a high need for new treatment options in recurrence. In three Phase I/II dose escalation trials with AP 12009 in high-grade glioma (HGG) patients complete and long lasting tumor responses had been observed. Methods: The study G004 is an international open-label, randomized, active controlled, dose-finding Phase IIb study. Objective is a comparison of two doses of AP 12009 and standard chemotherapy. A total of 145 patients with histopathologically confirmed recurrent or refractory HGG (WHO Grades III and IV) were randomized into three treatment arms. Patients received treatment with low dose AP 12009 (10 μM), high dose AP 12009 (80 μMM), or standard chemotherapy TMZ or PCV. AP 12009 was applied by convection-enhanced delivery during using 7-day-on, 7-day-off cycles. Maximum number of cycles was 11. Results: Here we report on patients with recurrent or refractory glioblastoma (GBM, WHO Grade IV; AA patients see separate abstract). Out of 95 GBM patients treated, 28 pts received 10 μM AP 12009, 34 pts AP 12009 80 μM, and 33 pts standard chemotherapy (28 TMZ, 5 PCV). Median age differed between treatment groups (see table ). Dose finding was achieved, as efficacy and safety results for the AP-10 group were superior to those of the AP-80 group (see table ). Comparable hazard ratios for survival were seen in the three treatment groups (see table ). Long lasting responses were observed in both AP 12009 groups. Conclusions: The safety profile of AP 12009 in GBM patients was good. The durable responses in both AP 12009 groups and the survival data confirm the proof of concept obtained in Phase I/II trials for treatment of recurrent GBM patients with AP 12009. [Table: see text] No significant financial relationships to disclose.
Collapse
Affiliation(s)
- P. Hau
- University of Regensburg, Regensburg, Germany; Polenov Neurosurgery Research Institute, St. Petersburg, Russian Federation; All India Institute of Medical Sciences, New Delhi, India; Military Medical Academy, St. Petersburg, Russian Federation; Manipal Institute for Neurological Disorders, Bangalore, India; Antisense Pharma GmbH, Regensburg, Germany
| | - U. Bogdahn
- University of Regensburg, Regensburg, Germany; Polenov Neurosurgery Research Institute, St. Petersburg, Russian Federation; All India Institute of Medical Sciences, New Delhi, India; Military Medical Academy, St. Petersburg, Russian Federation; Manipal Institute for Neurological Disorders, Bangalore, India; Antisense Pharma GmbH, Regensburg, Germany
| | - V. E. Olyushin
- University of Regensburg, Regensburg, Germany; Polenov Neurosurgery Research Institute, St. Petersburg, Russian Federation; All India Institute of Medical Sciences, New Delhi, India; Military Medical Academy, St. Petersburg, Russian Federation; Manipal Institute for Neurological Disorders, Bangalore, India; Antisense Pharma GmbH, Regensburg, Germany
| | - A. Mahapatra
- University of Regensburg, Regensburg, Germany; Polenov Neurosurgery Research Institute, St. Petersburg, Russian Federation; All India Institute of Medical Sciences, New Delhi, India; Military Medical Academy, St. Petersburg, Russian Federation; Manipal Institute for Neurological Disorders, Bangalore, India; Antisense Pharma GmbH, Regensburg, Germany
| | - V. E. Parfenov
- University of Regensburg, Regensburg, Germany; Polenov Neurosurgery Research Institute, St. Petersburg, Russian Federation; All India Institute of Medical Sciences, New Delhi, India; Military Medical Academy, St. Petersburg, Russian Federation; Manipal Institute for Neurological Disorders, Bangalore, India; Antisense Pharma GmbH, Regensburg, Germany
| | - K. Venkataramana
- University of Regensburg, Regensburg, Germany; Polenov Neurosurgery Research Institute, St. Petersburg, Russian Federation; All India Institute of Medical Sciences, New Delhi, India; Military Medical Academy, St. Petersburg, Russian Federation; Manipal Institute for Neurological Disorders, Bangalore, India; Antisense Pharma GmbH, Regensburg, Germany
| | - S. Ludwig
- University of Regensburg, Regensburg, Germany; Polenov Neurosurgery Research Institute, St. Petersburg, Russian Federation; All India Institute of Medical Sciences, New Delhi, India; Military Medical Academy, St. Petersburg, Russian Federation; Manipal Institute for Neurological Disorders, Bangalore, India; Antisense Pharma GmbH, Regensburg, Germany
| | - P. Jachimczak
- University of Regensburg, Regensburg, Germany; Polenov Neurosurgery Research Institute, St. Petersburg, Russian Federation; All India Institute of Medical Sciences, New Delhi, India; Military Medical Academy, St. Petersburg, Russian Federation; Manipal Institute for Neurological Disorders, Bangalore, India; Antisense Pharma GmbH, Regensburg, Germany
| | - H. Heinrichs
- University of Regensburg, Regensburg, Germany; Polenov Neurosurgery Research Institute, St. Petersburg, Russian Federation; All India Institute of Medical Sciences, New Delhi, India; Military Medical Academy, St. Petersburg, Russian Federation; Manipal Institute for Neurological Disorders, Bangalore, India; Antisense Pharma GmbH, Regensburg, Germany
| | - K. Schlingensiepen
- University of Regensburg, Regensburg, Germany; Polenov Neurosurgery Research Institute, St. Petersburg, Russian Federation; All India Institute of Medical Sciences, New Delhi, India; Military Medical Academy, St. Petersburg, Russian Federation; Manipal Institute for Neurological Disorders, Bangalore, India; Antisense Pharma GmbH, Regensburg, Germany
| |
Collapse
|
34
|
Kumar Gupta D, Suri A, Mahapatra A, Sarka C, Sharma B. Surgical Management of Petroclival Tumors: Defining Outcome/Resection Goals. Skull Base 2007. [DOI: 10.1055/s-2007-983943] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
35
|
Sinha S, Sharma B, Mahapatra A. Microsurgical Management of Giant Pituitary Adenomas: A Series of 177 Cases. Skull Base 2007. [DOI: 10.1055/s-2007-983989] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
36
|
Hau P, Stockhammer G, Kunst M, Mahapatra A, Sastry KV, Parfenov VE, Leshinsky VG, Jachimczak P, Bogdahn U, Schlingensiepen K. Results of G004, a phase IIb actively controlled clinical trial with the TGF-b2 targeted compound AP 12009 for recurrent anaplastic astrocytoma. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.1566] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
1566 Background: In 3 phase I/II dose-escalation studies the TGF-β2 specific compound AP 12009 proved to be well tolerated and revealed an excellent safety profile. Furthermore, antitumor activity including complete tumor remissions was observed. Methods: G004 is an international open-label, actively controlled, dose finding phase IIb trial in adult patients with histopathologically confirmed recurrent high-grade glioma. 145 patients with recurrent anaplastic astrocytoma (AA, WHO grade III) or glioblastoma (GBM, WHO grade IV) were enrolled into the study. Objective of the current phase IIb study is to compare the efficacy and safety of two doses of AP 12009 and standard treatment. Patients were randomized to receive either one of two doses of AP 12009 (10 μM or 80 μM) or standard chemotherapy (TMZ or PCV). AP 12009 was administered intratumorally by CED. 134 patients received treatment and all of them have completed active treatment. Primary endpoint is tumor response by local and central MRI reading and survival. Results: Here we report on patients with recurrent AA (for GBM see separate Abstract). 38 patients with AA (68% male, 32% female; median age 39, range 22–60; median Karnofsky performance status: 90, range 70–100) were treated. 26 patients received AP 12009 (10 μM or 80 μM), 12 patients were treated with TMZ or PCV. Up to now, in 89 patients treated with AP 12009 (both AA and GBM patients) 6 SAEs possibly related to the study drug and 37 procedure related SAEs (92% mild or moderate) were documented. Partial and complete tumor responses were observed. Exact response rates will be determined after central MRI reading is completed. Responses in the AP 12009 groups are long lasting. The results confirm the good safety profile of AP 12009 as well as the efficacy data seen in phase I studies. The median overall survival is not yet reached. Conclusions: The long-term tumor free survival of several patients may actually hint towards a potential to cure some patients with this devastating disease. Phase III clinical trials in both AA and GBM patients are currently in preparation. [Table: see text]
Collapse
Affiliation(s)
- P. Hau
- University of Regensburg, Regensburg, Germany; Universitätsklinik für Neurologie, Innsbruck, Austria; Antisense Pharma GmbH, Regensburg, Germany; All India Institute of Medical Sciences, New Delhi, India; National Institute of Mental Health & Neurosciences, Bangalore, India; Military Medical Academy, St. Petersburg, Russian Federation; Sverdlovsk Regional Oncological Clinic, Ekaterinburg, Russian Federation
| | - G. Stockhammer
- University of Regensburg, Regensburg, Germany; Universitätsklinik für Neurologie, Innsbruck, Austria; Antisense Pharma GmbH, Regensburg, Germany; All India Institute of Medical Sciences, New Delhi, India; National Institute of Mental Health & Neurosciences, Bangalore, India; Military Medical Academy, St. Petersburg, Russian Federation; Sverdlovsk Regional Oncological Clinic, Ekaterinburg, Russian Federation
| | - M. Kunst
- University of Regensburg, Regensburg, Germany; Universitätsklinik für Neurologie, Innsbruck, Austria; Antisense Pharma GmbH, Regensburg, Germany; All India Institute of Medical Sciences, New Delhi, India; National Institute of Mental Health & Neurosciences, Bangalore, India; Military Medical Academy, St. Petersburg, Russian Federation; Sverdlovsk Regional Oncological Clinic, Ekaterinburg, Russian Federation
| | - A. Mahapatra
- University of Regensburg, Regensburg, Germany; Universitätsklinik für Neurologie, Innsbruck, Austria; Antisense Pharma GmbH, Regensburg, Germany; All India Institute of Medical Sciences, New Delhi, India; National Institute of Mental Health & Neurosciences, Bangalore, India; Military Medical Academy, St. Petersburg, Russian Federation; Sverdlovsk Regional Oncological Clinic, Ekaterinburg, Russian Federation
| | - K. V. Sastry
- University of Regensburg, Regensburg, Germany; Universitätsklinik für Neurologie, Innsbruck, Austria; Antisense Pharma GmbH, Regensburg, Germany; All India Institute of Medical Sciences, New Delhi, India; National Institute of Mental Health & Neurosciences, Bangalore, India; Military Medical Academy, St. Petersburg, Russian Federation; Sverdlovsk Regional Oncological Clinic, Ekaterinburg, Russian Federation
| | - V. E. Parfenov
- University of Regensburg, Regensburg, Germany; Universitätsklinik für Neurologie, Innsbruck, Austria; Antisense Pharma GmbH, Regensburg, Germany; All India Institute of Medical Sciences, New Delhi, India; National Institute of Mental Health & Neurosciences, Bangalore, India; Military Medical Academy, St. Petersburg, Russian Federation; Sverdlovsk Regional Oncological Clinic, Ekaterinburg, Russian Federation
| | - V. G. Leshinsky
- University of Regensburg, Regensburg, Germany; Universitätsklinik für Neurologie, Innsbruck, Austria; Antisense Pharma GmbH, Regensburg, Germany; All India Institute of Medical Sciences, New Delhi, India; National Institute of Mental Health & Neurosciences, Bangalore, India; Military Medical Academy, St. Petersburg, Russian Federation; Sverdlovsk Regional Oncological Clinic, Ekaterinburg, Russian Federation
| | - P. Jachimczak
- University of Regensburg, Regensburg, Germany; Universitätsklinik für Neurologie, Innsbruck, Austria; Antisense Pharma GmbH, Regensburg, Germany; All India Institute of Medical Sciences, New Delhi, India; National Institute of Mental Health & Neurosciences, Bangalore, India; Military Medical Academy, St. Petersburg, Russian Federation; Sverdlovsk Regional Oncological Clinic, Ekaterinburg, Russian Federation
| | - U. Bogdahn
- University of Regensburg, Regensburg, Germany; Universitätsklinik für Neurologie, Innsbruck, Austria; Antisense Pharma GmbH, Regensburg, Germany; All India Institute of Medical Sciences, New Delhi, India; National Institute of Mental Health & Neurosciences, Bangalore, India; Military Medical Academy, St. Petersburg, Russian Federation; Sverdlovsk Regional Oncological Clinic, Ekaterinburg, Russian Federation
| | - K. Schlingensiepen
- University of Regensburg, Regensburg, Germany; Universitätsklinik für Neurologie, Innsbruck, Austria; Antisense Pharma GmbH, Regensburg, Germany; All India Institute of Medical Sciences, New Delhi, India; National Institute of Mental Health & Neurosciences, Bangalore, India; Military Medical Academy, St. Petersburg, Russian Federation; Sverdlovsk Regional Oncological Clinic, Ekaterinburg, Russian Federation
| |
Collapse
|
37
|
Bogdahn U, Oliushine VE, Parfenov VE, Kunst M, Mahapatra A, Sastry KV, Venkataramana KN, Jachimczak P, Hau P, Schlingensiepen K. Results of G004, a phase IIb study in recurrent glioblastoma patients with the TGF-b2 targeted compound AP 12009. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.1553] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
1553 Background: In high-grade glioma (HGG), TGF-β2 expression strongly correlates with tumor grade and is highly predictive of disease outcome. The compound AP 12009 inhibits TGF-β2 expression. Preclinical results revealed strong multimodal activity including reversal of TGF-β induced immunosuppression, inhibition of tumor cell migration and proliferation. In 3 preceding phase I/II dose escalation studies, 24 HGG patients had been treated with AP 12009. Methods: G004 is an international open-label, actively controlled, dose finding phase IIb study. Objective is a comparison of two doses of AP 12009 and standard chemotherapy for efficacy and safety. 145 patients with histopathologically confirmed recurrent anaplastic astrocytoma (AA, WHO grade III) or glioblastoma (GBM, WHO grade IV) were randomized into one of 3 treatment arms. 134 patients received treatment AP 12009 10μM, AP 12009 80μM or standard chemotherapy (TMZ or PCV). AP 12009 was applied locoregionally by convection-enhanced delivery during a 6-month active treatment period with 7-day-on, 7-day-off cycles. Primary endpoint is tumor response by local and central MRI reading. All patients have completed active treatment. Follow-up for survival and tumor response assessed by local and central MRI reading is ongoing. Results: Here we report on patients with recurrent GBM (AA see separate Abstract). 96 GBM patients (37% female, 63% male; median age 51 years, range 20–74; median Karnofsky performance status 90, range 70–100) have been treated. 63 GBM patients received AP 12009 (28 pt. 10 μM, 35 pt. 80 μM), 33 patients received standard chemotherapy. Data were evaluated by an independent Data and Safety Monitoring Board. Up to now, in 89 patients treated with AP 12009 (AA and GBM patients) 6 SAEs possibly related to the study drug and 37 procedure related SAEs (92% mild or moderate) were documented. Several long-term tumor responses were observed by local MRI reading. Exact response rates are being determined by central reading. Conclusions: Responses in patients treated with AP 12009 in both AA and GBM patients are long lasting with a good quality of life. Phase III clinical trials in AA and GBM patients are currently in preparation. [Table: see text]
Collapse
Affiliation(s)
- U. Bogdahn
- University of Regensburg, Regensburg, Germany; Polenov Neurosurgery Research Institute, St. Petersburg, Russian Federation; Military Medical Academy, St. Petersburg, Russian Federation; Antisense Pharma GmbH, Regensburg, Germany; All India Institute of Medical Sciences, New Delhi, India; National Institute of Mental Health & Neurosciences, Bangalore, India; Manipal Hospital, Bangalore, India
| | - V. E. Oliushine
- University of Regensburg, Regensburg, Germany; Polenov Neurosurgery Research Institute, St. Petersburg, Russian Federation; Military Medical Academy, St. Petersburg, Russian Federation; Antisense Pharma GmbH, Regensburg, Germany; All India Institute of Medical Sciences, New Delhi, India; National Institute of Mental Health & Neurosciences, Bangalore, India; Manipal Hospital, Bangalore, India
| | - V. E. Parfenov
- University of Regensburg, Regensburg, Germany; Polenov Neurosurgery Research Institute, St. Petersburg, Russian Federation; Military Medical Academy, St. Petersburg, Russian Federation; Antisense Pharma GmbH, Regensburg, Germany; All India Institute of Medical Sciences, New Delhi, India; National Institute of Mental Health & Neurosciences, Bangalore, India; Manipal Hospital, Bangalore, India
| | - M. Kunst
- University of Regensburg, Regensburg, Germany; Polenov Neurosurgery Research Institute, St. Petersburg, Russian Federation; Military Medical Academy, St. Petersburg, Russian Federation; Antisense Pharma GmbH, Regensburg, Germany; All India Institute of Medical Sciences, New Delhi, India; National Institute of Mental Health & Neurosciences, Bangalore, India; Manipal Hospital, Bangalore, India
| | - A. Mahapatra
- University of Regensburg, Regensburg, Germany; Polenov Neurosurgery Research Institute, St. Petersburg, Russian Federation; Military Medical Academy, St. Petersburg, Russian Federation; Antisense Pharma GmbH, Regensburg, Germany; All India Institute of Medical Sciences, New Delhi, India; National Institute of Mental Health & Neurosciences, Bangalore, India; Manipal Hospital, Bangalore, India
| | - K. V. Sastry
- University of Regensburg, Regensburg, Germany; Polenov Neurosurgery Research Institute, St. Petersburg, Russian Federation; Military Medical Academy, St. Petersburg, Russian Federation; Antisense Pharma GmbH, Regensburg, Germany; All India Institute of Medical Sciences, New Delhi, India; National Institute of Mental Health & Neurosciences, Bangalore, India; Manipal Hospital, Bangalore, India
| | - K. N. Venkataramana
- University of Regensburg, Regensburg, Germany; Polenov Neurosurgery Research Institute, St. Petersburg, Russian Federation; Military Medical Academy, St. Petersburg, Russian Federation; Antisense Pharma GmbH, Regensburg, Germany; All India Institute of Medical Sciences, New Delhi, India; National Institute of Mental Health & Neurosciences, Bangalore, India; Manipal Hospital, Bangalore, India
| | - P. Jachimczak
- University of Regensburg, Regensburg, Germany; Polenov Neurosurgery Research Institute, St. Petersburg, Russian Federation; Military Medical Academy, St. Petersburg, Russian Federation; Antisense Pharma GmbH, Regensburg, Germany; All India Institute of Medical Sciences, New Delhi, India; National Institute of Mental Health & Neurosciences, Bangalore, India; Manipal Hospital, Bangalore, India
| | - P. Hau
- University of Regensburg, Regensburg, Germany; Polenov Neurosurgery Research Institute, St. Petersburg, Russian Federation; Military Medical Academy, St. Petersburg, Russian Federation; Antisense Pharma GmbH, Regensburg, Germany; All India Institute of Medical Sciences, New Delhi, India; National Institute of Mental Health & Neurosciences, Bangalore, India; Manipal Hospital, Bangalore, India
| | - K. Schlingensiepen
- University of Regensburg, Regensburg, Germany; Polenov Neurosurgery Research Institute, St. Petersburg, Russian Federation; Military Medical Academy, St. Petersburg, Russian Federation; Antisense Pharma GmbH, Regensburg, Germany; All India Institute of Medical Sciences, New Delhi, India; National Institute of Mental Health & Neurosciences, Bangalore, India; Manipal Hospital, Bangalore, India
| |
Collapse
|
38
|
Mahapatra S, Mahapatra A, Tripathy S, Rath G, Dash AK, Mahapatra A. Mycobacterium avium intracellularae complex associated extrapulmonary axillary lymphadenitis in a HIV-seropositive infant--a rare case report. Indian J Med Microbiol 2005; 23:192-4. [PMID: 16100429 DOI: 10.4103/0255-0857.16594] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Opportunistic infections by Mycobacterium avium intracellulare complex in HIV infected patients, though common in adults, are rarely seen in infants. We herewith report an interesting case of an eight month old infant presenting with isolated axillary lymphadenitis, later on diagnosed to be tubercular lymphadenitis by Mycobacterium avium intracellulare and finally proved to be seropositive for HIV infection born to previously undetected HIV seropositive parents.
Collapse
Affiliation(s)
- S Mahapatra
- Department of Pathology, MKCG Medical College, Berhampur - 760 004, Ganjam Orissa, India.
| | | | | | | | | | | |
Collapse
|
39
|
Mahapatra S, Mahapatra A, Tripathy S, Rath G, Dash AK, Mahapatra A. MYCOBACTERIUM AVIUM INTRACELLULARAE COMPLEX ASSOCIATED EXTRAPULMONARY AXILLARY LYMPHADENITIS IN A HIV-SEROPOSITIVE INFANT — A RARE CASE REPORT. Indian J Med Microbiol 2005. [DOI: 10.1016/s0255-0857(21)02594-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
40
|
|
41
|
|
42
|
Padhi S, Panigrahi PK, Mahapatra A, Mahapatra S. Avian influenza A (H5N1): a preliminary review. Indian J Med Microbiol 2004; 22:143-6. [PMID: 17642720] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/16/2023]
Abstract
Humanity has been at the receiving end of many viral diseases since ages. Sudden emergence and re-emergence of new viral diseases in human beings has surprised the medical scientists from time to time. "Avian influenza" or "Bird flu" by H5N1 epidemics is one such surprise. Although many aspects about this disease are clear, there are some dark areas regarding vaccine development that need to be further explored and understood, so as to effectively contain the spread of this disease. The present article details out almost everything known about this interesting disease along with the review of the recent literature.
Collapse
Affiliation(s)
- S Padhi
- Department of Microbiology, MKCG Medical College, Berhampur, Orissa - 760 004, India
| | | | | | | |
Collapse
|
43
|
Padhi S, Mahapatra A, Pattnaik D, Chayani N, Mishra S, Mahapatra A. Bacterial meningitis due to Streptococcus milleri. Indian J Med Microbiol 2004; 22:130. [PMID: 17642713] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/16/2023]
|
44
|
Padhi S, Mahapatra A, Pattnaik D, Chayani N, Mishra S, Mahapatra A. Bacterial Meningitis due to Streptococcus milleri. Indian J Med Microbiol 2004. [DOI: 10.1016/s0255-0857(21)02897-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
45
|
Mishra S, Pattnaik D, Mahapatra A, Swain B. Pleural empyema due to S. typhi: a case report. INDIAN J PATHOL MICR 2004; 47:75-6. [PMID: 15471141] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/30/2023] Open
Abstract
In a 35 year old immunocompetent male, clinically diagnosed as a case of hydropneumothorax of left side, Salmonella typhi was isolated as the causative agent of pleural empyema.
Collapse
Affiliation(s)
- S Mishra
- Department of Microbiology, M.K.C. G. Medical College, Berhampur
| | | | | | | |
Collapse
|
46
|
Mahapatra A, Mishra S, Pattnaik D, Patnaik K. Bacterial endocarditis due to Eikenella corrodens: a case report. Indian J Med Microbiol 2003; 21:135-6. [PMID: 17643001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/16/2023]
Abstract
Of all the causes of bacterial endocarditis, HACEK group consisting of Haemophilus, Actinobacillus actinomycetemcomitans, Cardiobacterium hominis, Eikenella corrodens, and Kingella Kingae are rare causative agents. We report a case of bacterial endocarditis by E. corrodens, which is one of the members of the HACEK group.
Collapse
Affiliation(s)
- A Mahapatra
- Department of Microbiology, MKCG Medical College, Berhampur - 760 004, Ganjam, Orissa, India
| | | | | | | |
Collapse
|
47
|
|
48
|
Sousa J, Sharma RR, Pawar SJ, Mahapatra A, Lad SD. Long term outcome in patients with severe head injury and bilateral fixed dilated pupils. Neurol India 2002; 50:430-5. [PMID: 12577090] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/28/2023]
Abstract
Patients with severe head injury with bilateral dilated unreactive pupils are considered to have a grave prognosis. Hence proper planning and aggressive management becomes mandatory for achieving good results. We present the outcome of consecutive 166 patients with severe head injury, admitted between January 1996 and December 2000 and analysed retrospectively. All the patients had an initial GCS of 8 or less and post resuscitation bilateral dilated unreactive pupils. Our aim was to analyze the long term outcome in these patients and identify the other significant prognostic factors. Of the 166 patients, 42 (25.30%) had a functional outcome (good recovery in 10.24%, moderate disability in 15.06%), and 124 (74.69%) had a poor outcome (death in 58.43% and severe disability in 16.26% of cases). There were 45 patients with polytrauma and 24 of these patients (53.33%) succumbed to the injuries. Obliteration of the basal cisterns and contusion were the common CT scan findings. Factors adversely affecting the survival included age of the patient, polytrauma with shock, initial GCS of 3 or 4, and compression of the basal cisterns on the initial CT scans. At follow up, most of the patients with a functional outcome showed a significant improvement in their motor function but continued to have neuro-behavioral and cognitive deficits.
Collapse
Affiliation(s)
- J Sousa
- Department of Neurosurgery, Khoula Hospital, Muscat 116, Sultanate of Oman
| | | | | | | | | |
Collapse
|
49
|
Mahapatra A, Ghosh SK, Mishra S, Pattnaik D, Pattnaik K, Mohanty SK. Enterobacter cloacae: a predominant pathogen in neonatal septicaemia. Indian J Med Microbiol 2002; 20:110-2. [PMID: 17657046] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/16/2023]
Abstract
A total of 120 blood samples from neonates presenting with clinical signs of septicaemia were subjected for culture using brain heart infusion agar biphasic medium (BHI BPM) and glucose broth. Bacterial agents were isolated from 48 numbers (40%) of cultures. Gram-negative bacilli were isolated in maximum percentage (88.45%) of cases whereas gram-positive bacteria (coagulase negative staphylococci and group B streptococci) in 11.6% of cultures. E. cloacae (39.5%) was maximally isolated among the pathogenic bacteria followed by K. pneumoniae (23.2%), E. coli (11.6%) and others like Acinetobacter spp. (6.9%), Citrobacter freundi (4.6%) and P. mirabillis (2.3%). All the gram-negative bacilli isolates showed 100% susceptibility to amikacin, whereas 85% of E. cloacae isolates were sensitive to the same. Thus E. cloacae was found to be a predominant moderately sensitive pathogen in neonatal septicemia.
Collapse
Affiliation(s)
- A Mahapatra
- Dept. of Microbiology MKCG Medical College, Berhampur - 760 004, Orissa, India
| | | | | | | | | | | |
Collapse
|
50
|
Sousa J, Sharma RR, Pawar SJ, Mahapatra A, Mishra GP. Solitary skull metastasis from mucoepidermoid mimicking a parotid tumour. Neurol India 2001; 49:194-6. [PMID: 11447446] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/20/2023]
Abstract
Metastatic parotid tumours in the skull are very rare. An interesting case of a mucoepidermoid parotid tumour metastasizing to the skull vault is described in a patient who had previously been operated for a pituitary adenoma 20 years back with no post operative radiotherapy; however, she required hormonal supplementation therapy. She underwent an operation for a parotid tumour 7 years ago and received postoperative radiotherapy for the parotid tumour away from the site of the skull metastases. No local recurrence of the parotid tumour was noted. The initial diagnosis was that of a solitary intradiploic meningioma. Interesting clinico-radiological findings are presented.
Collapse
Affiliation(s)
- J Sousa
- Department of Neurosurgery, The National Neurosurgical Centre, Khoula Hospital, Post Box-90, Postal Code - 116, Mina-Al-Fahal, Muscat, Oman
| | | | | | | | | |
Collapse
|